A digital health investor’s perspective: digital therapeutics (DTx)

"Kicking off this new series of articles, in which we will be sharing views on several digital health-related topics, from our perspective as early-stage investors
Digital Therapeutics (DTx) have been in the spot light for some time now and the picture is starting to get clearer. Multiple start-up/pharma partnerships, FDA approvals and (finally) substantial M&A action (i.e. Teladoc acquiring Livongo for US$18.5 bn in October 2020) are all signs pointing towards the maturation of the sector. Even regulators & payers are working on ways to better assess and support this new class of treatment: the best example being Germany, which enacted the Digital Care Act (DVG) in 2020 to provide early reimbursement to digital therapies. In this article we will share our perspective on some of the opportunities and challenges of DTx..." Lire la suite